FDA Approves Maintenance Tucatinib for Advanced HER2+ Breast Cancer

The U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) on October 7, 2026, in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

This indication applies to patients without disease progression following induction therapy with 4 to 8 cycles of trastuzumab, pertuzumab, and a taxane. Tucatinib is an oral tyrosine kinase inhibitor targeting HER2.

Clinical Efficacy Data From HER2CLIMB-05

FDA approval was supported by efficacy and safety results from HER2CLIMB-05 (NCT05132582), a randomized, double-blind, placebo-controlled trial enrolling 654 adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer, including patients with or without brain metastases.

Participants were randomized to receive tucatinib 300 mg orally twice daily or placebo, combined with intravenous trastuzumab and pertuzumab or a fixed-dose subcutaneous combination of trastuzumab, pertuzumab, and hyaluronidase. Patients with hormone receptor-positive disease were permitted to continue concomitant endocrine therapy.

The primary outcome measure was investigator-assessed progression-free survival (PFS) using RECIST v1.1. Median PFS reached 24.9 months (95% CI: 21.3, not reached) in the tucatinib arm compared with 16.3 months (95% CI: 12.6, 18.7) in the placebo arm (hazard ratio 0.64; 95% CI: 0.51, 0.80; p < 0.0001). Overall survival data were immature at the time of PFS analysis.

Key Clinical Takeaways for Oncology Nurses: Efficacy and Administration

• Target Population Eligibility: Verify that patients have unresectable locally advanced or metastatic HER2-positive disease and completed 4 to 8 cycles of induction trastuzumab, pertuzumab, and a taxane without disease progression prior to initiating maintenance tucatinib.
• Statistically Significant PFS Extension: Maintenance tucatinib reduced the risk of disease progression or death by 36% compared with placebo, achieving a median PFS of 24.9 months versus 16.3 months (HR 0.64; p < 0.0001).
• Dosing and Route Options: Administer tucatinib at 300 mg orally twice daily alongside intravenous or subcutaneous fixed-dose trastuzumab and pertuzumab until disease progression or unmanageable toxicity.
• Endocrine Therapy Continuation: Ensure eligible patients with hormone receptor-positive disease maintain prescribed endocrine therapy during maintenance treatment.

Safety Profile, Warnings, and Adverse Event Management

The prescribing information for tucatinib contains a Boxed Warning for hepatotoxicity. Additional warnings and precautions include severe diarrhea, embryo-fetal toxicity, and elevations in serum creatinine without affecting renal function.

Healthcare teams should monitor liver function tests—including ALT, AST, and total bilirubin—at baseline and periodically throughout therapy. Serum creatinine elevations require clinical contextualization, as tucatinib inhibits renal tubular secretion of creatinine without impairing actual glomerular filtration rate or true renal function.

Key Clinical Takeaways for Oncology Nurses: Toxicity and Patient Management

• Hepatotoxicity Monitoring: Perform baseline and routine liver function evaluations due to the Boxed Warning for severe drug-induced liver injury.
• Diarrhea Management Protocols: Educate patients on immediate reporting of loose stools; initiate antidiarrheal therapy, oral hydration, and dose holds or modifications according to protocol severity thresholds.
• Creatinine Elevation Contextualization: Differentiate tucatinib-induced benign serum creatinine increases from true acute kidney injury to avoid unnecessary treatment interruptions.
• Reproductive Safety Counseling: Verify negative pregnancy status in females of reproductive potential and counsel patients regarding effective contraception due to risks of embryo-fetal toxicity.

Reference

1. U.S. Food and Drug Administration. FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer. Published October 7, 2026. Accessed October 7, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer